Ota, Mitsuhiko
Saeki, Hiroshi http://orcid.org/0000-0001-7243-6960
Uehara, Hideo
Matsuda, Yoshiko
Tsutsumi, Satoshi
Kusumoto, Tetsuya
Yasui, Hisateru
Ubukata, Yasunari
Yamaguchi, Shohei
Orita, Hiroyuki
Izawa, Naoki
Kakizoe, Saburo
Shimokawa, Mototsugu
Yoshizumi, Tomoharu
Kakeji, Yoshihiro
Mori, Masaki
Oki, Eiji
Funding for this research was provided by:
Yakult Honsha Co., Ltd. Head Office
CReS Kyushu
Article History
Received: 3 May 2023
Accepted: 16 June 2023
First Online: 27 June 2023
Declarations
:
: Hiroshi Saeki (Department of General Surgical Science, Graduate School of Medicine, Gunma University), who is the Research Director of this study, is not in a state of conflict of interest with the Yakult Honsha Co., Ltd. Head Office. Y. Kakeji has received an honorarium from Taiho Pharmaceutical Co., Ltd. N. Izawa received research grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sanofi K.K., Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and honoraria from Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd. E. Oki received honoraria from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., and Takeda Pharmaceutical Co., Ltd. M. Ota received honoraria from Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Daiichi Sankyo Co., Ltd. All remaining authors have declared no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by the Clinical Research Network Fukuoka Certified Review Board (Certification No. CRB7180004). Informed consent to be included in the study, or the equivalent, was obtained from all patients.